A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis

This Phase II study will compare the efficacy and safety of obinutuzumab plus mycophenolate mofetil (MMF)/mycophenolic acid (MPA) with placebo plus MMF/MPA in participants with proliferative LN.

Study Overview

• Status: Completed
• Conditions: Lupus Nephritis
• Intervention / Treatment: Drug: Mycophenolate Mofetil/Mycophenolic Acid; Drug: Obinutuzumab; Drug: Methylprednisolone; Drug: Prednisone; Other: Placebo

• Study Type: Interventional
• Enrollment (Actual): 126
• Phase: Phase 2

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina, C1431FWO
    • Cemic; Haematology
  • San Juan, Argentina, J5400DIL
    • CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica
  • San Nicolás, Argentina, C1015ABO
    • Organización Médica de Investigación
• Brazil
  • BA
    • Salvador, BA, Brazil, 40150-150
      • Ser Servicos Especializados Em Reumatologia
  • MG
    • Belo Horizonte, MG, Brazil, 31270-901
      • Hospital das Clinicas - UFMG
    • Juiz de Fora, MG, Brazil, 36010-570
      • Centro Mineiro de Pesquisa - CMIP
  • PR
    • Curitiba, PR, Brazil, 80440-020
      • Instituto Scribner.
  • RS
    • Porto Alegre, RS, Brazil, 90480-000
      • LMK Serviços Médicos S/S
  • SP
    • Sao Paulo, SP, Brazil, 04026-000
      • Universidade Federal de Sao Paulo - UNIFES
• Colombia
  • Barranquilla, Colombia, 080020
    • Clinica De La Costa
  • Bogota, Colombia, 000472
    • Hospital Universitario San Ignacio
  • Bogota, Colombia
    • Riesgo De Fractura; Rheumatology
  • Medellin, Colombia, 050034
    • Hospital Pablo Tobon Uribe
• Costa Rica
  • Goicoechea, Costa Rica, 10801
    • Hospital Clínica Católica
• France
  • Creteil, France, 94010
    • HOPITAL HENRI MONDOR; SERVICE DE Nephrologie
  • Lille, France, 59037
    • Hopital Claude Huriez; Internal Medicine
  • Marseille, France, 13003
    • Hopital europeen Marseille; Service de medecine interne
  • Paris, France, 75651
    • Groupe Hospitalier Pitie-Salpetriere; Service de Medecine Interne Ii
  • Paris, France, 75877
    • Hopital Bichat Claude Bernard; Nephrologie
  • Toulouse, France, 31059
    • Hopital Rangueil; Service de Nephrologie & D'Immunologie Clinique
• Israel
  • Haifa, Israel, 3109601
    • Rambam Medical Center; Rheumatology
  • Petach Tikva, Israel, 4941492
    • Beilinson Medical Center; Rheumatology
  • Ramat Gan, Israel, 5262100
    • Sheba Medical Center; Tel Hashomer
• Italy
  • Piemonte
    • Torino, Piemonte, Italy, 10154
      • Ospedale San Giovanni Bosco; entro di Ricerche di Immunopatologia e Documentazione su Malattie Rare
  • Veneto
    • Padova, Veneto, Italy, 35128
      • Azienda Ospedaliera di Padova; Dipartimento di Medicina - UOC di Reumatologia
• Mexico
  • BAJA California
    • Mexicali, BAJA California, Mexico, 21100
      • Unidad de Reumatologia Rehabilitacion Integral; Centro Medico Del Angel
  • Jalisco
    • Guadalajara, Jalisco, Mexico, 44620
      • Unidad de Investigacion en Enfermedades Cronico-Degenerativa; Reumatologia
    • Guadalajara, Jalisco, Mexico, 44690
      • Centro de Estudios de Investigacion Basica Y Clinica S.C.; Reumatologia
  • Mexico CITY (federal District)
    • Mexico City, Mexico CITY (federal District), Mexico, Tlalpan 14000
      • Instituto Nacional de Ciencias Médicas Y de La Nutricion Zubirán
    • Mexico, D.F., Mexico CITY (federal District), Mexico, 6726
      • Hospital General De Mexico; Rheumatology
  • Michoacan
    • Morelia, Michoacan, Mexico, 58070
      • Centro de Investigación Clínica de Morelia S.C.
  • Sinaloa
    • Culiacán Rosales, Sinaloa, Mexico, 80000
      • Centro de Investigación de Tratamientos Innovadores de Sinaloa (CITI)
• Panama
  • Panama, Panama, 0801
    • Trial Labs
• Peru
  • Lima, Peru
    • Instituto de Ginecología y Reproducción
  • Miraflores, Peru, 15074
    • Centro de Investigación Delgado; Clinica Delgado
  • San Juan de Miraflores, Peru, 15801
    • Centro de Investigaciones Medicas/Hospital Maria Auxiliadora
  • San Martin de Porres, Peru, 15102
    • Hospital Nacional Cayetano Heredia; Rheumatology
• Spain
  • Barcelona, Spain, 08036
    • Hospital Clinic i Provincial; Servicio de Nefrologia
  • Malaga, Spain, 29009
    • Hospital Regional Universitario Carlos Haya; Servicio de Reumatologia
• United States
  • California
    • La Jolla, California, United States, 92093
      • Univ of California, San Diego
    • Palo Alto, California, United States, 94304
      • Stanford University Medical Center
  • Georgia
    • Atlanta, Georgia, United States, 30303
      • Emory Uni ; Division of Rheumatology
  • New York
    • Brooklyn, New York, United States, 11203
      • Suny Downstate Medical Center; Rheumatology
    • Great Neck, New York, United States, 11021
      • North Shore - Long Island Jewish Hospital Health System; Rheumatology & Allergy- Clinical Immunology
    • New York, New York, United States, 10032
      • Columbia University Medical Center
  • Ohio
    • Columbus, Ohio, United States, 43210
      • Ohio State University; Division of Nephrology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnosis of Systemic Lupus Erythematosus (SLE), according to current American College of Rheumatology (ACR) criteria
• Diagnosis of International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV LN as evidenced by renal biopsy performed within 6 months prior to or during screening. Participants may co-exhibit Class V disease in addition to either Class III or Class IV disease
• Proteinuria (urine protein to creatinine ratio) greater than (>) 1.0
• For women who are not postmenopausal (greater than or equal to [>/=] 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of less than (<) 1 percent (%) per year, during the treatment period and for at least 18 months after the last dose of study drug
• For men: agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 12 months after the last dose of study drug and agreement to refrain from donating sperm during this same period

Exclusion Criteria:

• Retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke or stroke syndrome, cerebellar ataxia, or dementia that is currently active and resulting from SLE
• Presence of rapidly progressive glomerulonephritis
• Severe renal impairment as defined by estimated Glomerular Filtration Rate (GFR) <30 milliliters per minute (mL/min) or the need for dialysis or renal transplant
• Greater than 50% of glomeruli with sclerosis on renal biopsy
• Treatment with cyclophosphamide or calcineurin inhibitors within the 3 months prior to randomization
• Unstable disease with thrombocytopenia or at high risk for developing clinically significant bleeding or organ dysfunction requiring therapies such as plasmapheresis or acute blood or platelet transfusions
• History of severe allergic or anaphylactic reactions to monoclonal antibodies or known hypersensitivity to any component of the obinutuzumab infusion
• Significant or uncontrolled medical disease in any organ system not related to SLE or LN, which, in the investigator's opinion, would preclude participant participation
• Concomitant chronic conditions, excluding SLE, (e.g., asthma, Crohn's disease) that required oral or systemic steroid use in the 52 weeks prior to screening
• Previous treatment with an anti-cluster of differentiation (CD20)-targeted therapy within 12 months
• Previous treatment with a biologic B-cell-targeted therapy (other than anti-CD20) within 6 months of randomization
• Known intolerance to MMF or MPA

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Obinutuzumab; Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.	Drug: Mycophenolate Mofetil/Mycophenolic Acid; MMF/MPA will be administered as per schedule specified in the respective arm.; Drug: Obinutuzumab; Obinutuzumab will be administered as per schedule specified in the respective arm.; Other Names: Gazyva, GA101, RO5072759; Drug: Methylprednisolone; Methylprednisolone IV will be administered as per schedule specified in the respective arm.; Drug: Prednisone; Prednisone will be administered as per schedule specified in the respective arm.
Placebo Comparator: Placebo; Participants will receive placebo matching to obinutuzumab IV infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 g/day (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.	Drug: Mycophenolate Mofetil/Mycophenolic Acid; MMF/MPA will be administered as per schedule specified in the respective arm.; Drug: Methylprednisolone; Methylprednisolone IV will be administered as per schedule specified in the respective arm.; Drug: Prednisone; Prednisone will be administered as per schedule specified in the respective arm.; Other: Placebo; Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who Achieve Protocol Defined Complete Renal Response (CRR) at Week 52	Percentage of participants with normalization of serum creatinine, inactive urinary sediment (as evidenced by < 10 red blood cells (RBCs)/high-power field (HPF) and the absence of red cell casts) and urinary protein to creatinine ratio < 0.5. Normalization of serum creatinine is defined as serum creatinine ≤ the upper limit of normal (ULN) range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤ 15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values.	From baseline to Week 52

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who Achieve Protocol Defined Overall Response (OR) at Week 52	OR includes both CRR and partial renal response (PRR). CRR as defined in the primary outcome measure above. PRR defined as 50% improvement in urine protein:creatinine ratio, with one of following conditions met: 1. If baseline urine protein:creatinine ratio is ≤ 3.0, then urine protein:creatinine ratio of <1.0. 2. If baseline protein:creatinine ratio is > 3.0, then urine protein:creatinine ratio of <3.0, serum creatinine ≤15% above baseline value, and no urinary red cell casts and either RBCs/HPF ≤50% above baseline or <10 RBCs/HPF.	From baseline to Week 52
Percentage of Participants With First Protocol Defined Overall Response Over the Course of 52 Weeks	OR includes both CRR and partial renal response(PRR). CRR as defined in the primary outcome measure above. PRR defined as 50% improvement in upcr, with one of these conditions met: 1. If baseline upcr is ≤3.0, then upcr of <1.0. 2. If baseline pcr is > 3.0, then upcr of <3.0, serum creatinine ≤15% above baseline value, and no urinary red cell casts and either RBCs/HPF ≤50% above baseline or <10 RBCs/HPF. Percentage of participants with response at various time points were measured using Kaplan Meier method.	From baseline to Week 52
Percentage of Participants Who Achieve Protocol Defined Partial Renal Response (PRR) at Week 52	PRR defined as serum creatinine ≤15% above baseline value, no urinary red cell casts and either RBCs/HPF ≤ 50% above baseline or < 10 RBCs/HPF, 50% improvement in urine protein:creatinine ratio, with one of following conditions met: 1. If baseline urine protein:creatinine ratio is ≤ 3.0, then a urine protein:creatinine ratio of < 1.0. 2. If baseline protein:creatinine ratio is > 3.0, then a urine protein:creatinine ratio of < 3.0.	From baseline to Week 52
Percentage of Participants Who Achieve Protocol Defined CRR at Week 24	CRR defined as normalization of serum creatinine, inactive urinary sediment (as evidenced by < 10 red blood cells (RBCs)/high-power field (HPF) and the absence of red cell casts) and urinary protein to creatinine ratio < 0.5. Normalization of serum creatinine is defined as serum creatinine ≤ the upper limit of normal (ULN) range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤ 15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values.	Week 24
Percentage of Participants With First Protocol Defined CRR Over the Course of 52 Weeks	CRR included normalization of serum creatinine, inactive urinary sediment (as evidenced by < 10 RBCs/HPF and the absence of red cell casts) and urinary protein to creatinine ratio < 0.5. Normalization of serum creatinine is defined as serum creatinine ≤ the ULN range of central laboratory values if baseline serum creatinine is above the ULN or serum creatinine ≤ 15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values. Percentage of participants with response at various time points were measured using Kaplan Meier method.	From Baseline to Week 52
Change From Baseline in Anti-Double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Antibody Levels at Week 52	Anti-dsDNA antibodies are a group of anti-nuclear antibodies targeting double stranded DNA.	Baseline and Week 52
Change From Baseline in Complement Component 3 (C3) Levels at Week 52	Complement C3 is a blood test that reflects activation of complement pathway associated with immune deposition in certain autoimmune diseases.	Baseline and Week 52
Change From Baseline in C4 Levels at Week 52	Complement C4 is a blood test that reflects activation of complement pathway associated with immune deposition in certain autoimmune diseases.	Baseline, Week 52
Percentage of Participants Who Achieve Protocol Defined Modified CRR (mCRR1) at Week 52	mCRR1 has got two components only, i.e. serum Creatinine and urinary protein to creatinine ratio. mCRR1 is defined by attainment of normalization of serum creatinine as evidenced by 1.) serum creatinine ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine ≤ the ULN range of central laboratory values and 2.) Urinary protein to creatinine ratio <0.5.	Week 52
Percentage of Participants Who Achieve Protocol Defined Second mCRR (mCRR2) at Week 52	mCRR2 is defined by normalization of serum creatinine, inactive urinary sediment (as evidenced by < 10 RBCs/HPF and the absence of red cell casts), and urinary protein to creatinine ratio <0.5. Normalization of serum creatinine as evidenced by the following: Serum creatinine ≤15% above baseline if baseline (Day 1) serum creatinine is above the normal range of the central laboratory values or ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is ≤ the ULN range of central laboratory values.	Week 52
Percentage of Participants Who Achieve Protocol Defined Third mCRR (mCRR3) at Week 52	mCRR3 is defined by normalization of serum creatine as evidenced by serum creatinine ≤ the ULN range of central laboratory values and urinary protein to creatinine ratio < 0.5.	Week 52
Percentage of Participants With Adverse Events (AEs)	An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs), Infections and Serious infections.	From Baseline up to Week 104
Percentage of Participants With Adverse Events of Special Interest: Infusion Related Reactions, Grade 3 or Higher Infections, Drug-related Neutropenia and Drug-related Thrombocytopenia	Infusion related reaction is defined as any event reported within 24 hours of infusion and thought to be causally related to the investigational agent by the investigator. Grade 3 or higher infections include all events of Grade 3 to 5 under the SOC of infections and infestations. Drug-related neutropenia is defined as events in the Roche AE Grouped Term (AEGT) "Neutropenia and associated complications" and thought to be causally related to the investigational agent by the investigator. Drug-related thrombocytopenia is defined as events in the Standard MedDRA Query (SMQ) "Haematopoietic Thrombocytopenia narrow" and thought to be causally related to the investigational agent by the investigator.	From baseline up to Week 104
Percentage of Participants With Anti-Drug Antibody (ADA) to Obinutuzumab	Antibodies are a blood protein produced in response to and counteracting a specific antigen.	From baseline up to Week 104
Percent Change From Baseline in Circulating CD19-Positive B-Cell Levels	CD19+ B cell is a B-lymphocyte with a transmembrane protein that is encoded by the gene CD19.	Baseline, Week 2, Week 4, Week 12, Week 24, Week 52
Maximum Observed Plasma Concentration (Cmax) of Obinutuzumab		Week 0, Week 24, Week 52
Area Under the Plasma Concentration Versus Time Curve (AUC) of Obinutuzumab		Week 0, Week 24, Week 52
Systemic Clearance of Obinutuzumab		Day 0, Week 24, Week 52
Volume of Distribution Under Steady State (Vss) of Obinutuzumab		Day 0, Week 24, Week 52
Terminal Plasma Half-Life (t1/2) of Obinutuzumab		Day 0, Week 24, Week 52
Change From Baseline of Participant's Global Assessment of Disease Activity Visual Analog Scale (VAS) Score	Each VAS had a range from 0-100 with higher scores indicating greater symptom impact on global health status.	Baseline (Day 1), Weeks 4, 12, 24, 36, 52

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche
• Investigators: Study Director: Clinical Trials, Hoffmann-La Roche

Publications and helpful links

General Publications

• Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, Fragoso-Loyo H, Zuta-Santillan E, Schindler T, Brunetta P, Looney CM, Hassan I, Malvar A. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022 Jan;81(1):100-107. doi: 10.1136/annrheumdis-2021-220920. Epub 2021 Oct 6.
• Dossier C, Hogan J. Response to Majeranowski. Pediatr Nephrol. 2021 Jun;36(6):1653. doi: 10.1007/s00467-021-04982-4. Epub 2021 Mar 10. No abstract available.

Study record dates

Study Major Dates

• Study Start (Actual): November 13, 2015
• Primary Completion (Actual): January 15, 2019
• Study Completion (Actual): August 2, 2023

Study Registration Dates

• First Submitted: September 14, 2015
• First Submitted That Met QC Criteria: September 14, 2015
• First Posted (Estimated): September 15, 2015

Study Record Updates

• Last Update Posted (Actual): October 26, 2023
• Last Update Submitted That Met QC Criteria: October 20, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Kidney Diseases; Urologic Diseases; Connective Tissue Diseases; Glomerulonephritis; Lupus Erythematosus, Systemic; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Nephritis; Lupus Nephritis; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Autonomic Agents; Peripheral Nervous System Agents; Enzyme Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Antiemetics; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Neuroprotective Agents; Protective Agents; Antineoplastic Agents, Immunological; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antitubercular Agents; Antibiotics, Antitubercular; Methylprednisolone; Prednisone; Mycophenolic Acid; Obinutuzumab
• Other Study ID Numbers: WA29748; 2015-002022-39 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).